Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials
Abstract Background Schizophrenia is a complex psychiatric disorder characterized by positive, negative, and cognitive symptoms. KarXT, a novel combination of xanomeline and trospium, offers potential therapeutic benefits for schizophrenia treatment by targeting muscarinic receptors and avoiding dop...
Sparad:
| Huvudupphov: | , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
BMC
2025-03-01
|
| Serie: | BMC Psychiatry |
| Ämnen: | |
| Länkar: | https://doi.org/10.1186/s12888-025-06696-5 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|